Clinical OMICS

NOV-DEC 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 21 of 47

20 Clinical OMICs November/December 2017 Malorye Allison Branca Point–of–Care Testing Revs Up A host of new technologies and tests are allowing faster diagnosis and improved patient care across a range of conditions I t's a small, handheld, digital device that resembles a computer mouse but can measure a range of biological markers, including circulating tumor DNA (ctDNA) from blood and urine. Sounds a bit like science fiction, but in April of this year, Two Pore Guys (2PG) raised $24 million to help further develop this product, their Molecular Meter. 2PG's nanopore-based, single-molecule platform is one of a wave of next-gen- eration technologies revolutionizing point-of-care (POC) testing. These new tech- nologies extend the breadth of highly accurate tests that can be done anywhere a patient receives care, including in their own home. Critically, most of these tests automatically transmit data to a doctor 's office, a cloud-based account, or wherever else the information is needed. That's pivotal, because getting test results to the doctors, and making sure the results are stored for future use, are typically hurdles when testing is conducted in settings outside a central lab. POC testing has long been central to providing fast diagno- sis in the care setting, but there testing has not traditionally broken significant new ground. Now, the field is rising from the shadows and taking a more central role as the care settings offering these tests expands and the focus on value-based care intensifies. The goal is cheaper, simpler more reliable tests, as well as the ability to address more conditions with technology that can provide accurate results in a wider range of settings. These factors are expected to drive the POC market to almost $37 billion by 2021, according to Markets and Markets. Omics-based tests will play a prominent role in that growth, accounting for about 10% of that market. Growth will be particularly high for omics-based "In 2017 there is no reason a woman with a BRCA mutation should die of breast or ovarian cancer."—Jill Hagenkord, CMO, Color Geomics

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2017